Randomized, phase II trial to assess hypofractionated post-operative radiotherapy vs. conventional post-operative radiotherapy after surgical resection of invasive thymic tumors

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300067489

Enrollment

Unknown

Registered

2023-01-10

Start date

2023-01-10

Completion date

Unknown

Last updated

2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

thymic tumor

Interventions

conventional RT group:received conventional adjuvant radiotherapy (R0: 50Gy/25f

R1: 54Gy/27f

R2: 60-70Gy/30-35f)

moderately hypo-RT group:received adjuvant moderately hypofractionated radiotherapy (R0: 45Gy/15f

R1: 48Gy/16f

R2: 54-60Gy/18-20f)

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: ? pathologicaly diagnosed thymoma or thymic carcinoma ? received surgical resection a) R1,R2 resection b) For R0 resection, the thymoma stage should be Masaoka stage II-III; Thymic carcinoma has no requirement; ? Aged 18-75 ? KPS > 80 5. Cardiopulmonary function can tolerate surgery and radiotherapy

Exclusion criteria

Exclusion criteria: ? received induction chemotherapy ? received thoracic radiotherapy within 3 years ? complicated with other tumors or medical diseases that seriously affect prognosis ? inability to tolerate radiotherapy

Design outcomes

Primary

Measure	Time frame
overall survival;	—

Secondary

Measure	Time frame
disease-free survival;radiation pneumonitis;radiation esophagitis;radiation heart injury;relationship between parameters in preoperative PET-CT and survival;	—

Countries

China

Contacts

Public ContactDu Shisuo

Zhongshan Hospital, Fudan University

du.shisuo@zs-hospital.sh.cn13621830381

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026